

CIGB / BioCubaFarma — Cuba's State Biotechnology Technology-Transfer Engine

City Innovation Library · Good practice · Cuba

Quality score: 52/100

Evidence strength: Descriptive / self-reported

Summary

Cuba's CIGB, part of the BioCubaFarma group since 2012, holds 2,438 patents registered outside Cuba and sells in 50+ countries; during COVID-19 it transferred vaccine tech to Iran, Vietnam, Venezuela and Nicaragua, though figures are largely self-reported under a US embargo.

Key dimensions

Dimension	Score
Evidence of impact / measured results	2/3
Transferability / demonstrated replication	2/3
Scalability	2/3
Sustainability / continuity	2/3
Innovation	2/3
Inclusiveness / equity	0/3
Multi-stakeholder collaboration	1/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-08-16

[Centro de Ingeniería Genética y Biotecnología \(CIGB\) / BioCubaFarma](#) — accessed 2026-08-16

[Nature — BioCubaFarma: bringing Cuban biopharma to the world](#) — accessed 2026-08-16

[WHO/IRIS — Cuban experience with local production of medicines, technology transfer](#) — accessed 2026-08-16

[WIPO — Innovation and Technology Transfer in Cuba](#) — accessed 2026-08-16

Cite this — Evidoria. *CIGB / BioCubaFarma — Cuba's State Biotechnology Technology-Transfer Engine*. Persistent ID: acf3d265-5aa7-4d2c-be0f-afc947499057.